Effects on cell viability

Handbook of Experimental Pharmacology

Volumn 168, Issue , 2005, Pages 627-642

  Guzman M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Apoptosis; Cancer; Cell death; Cell proliferation; Neuroprotection

Indexed keywords

EID: 84855339807     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-26573-2_21     Document Type: Article

References (87)

1. Abood ME, Rizvi G, Sallapudi N, McAllister SD (2001) Activation of the CB1 cannabinoid receptor protects cultured spinal neurons against neurotoxicity. Neurosci Lett 309:197-201
2. Alberich Jordà M, Lowenberg B, Delwel R (2003) The peripheral cannabinoid receptor Cb2, a novel oncoprotein, induces a reversible block in neutrophilic differentiation. Blood 101:1336-1343
3. Arévalo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C (2003) Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23:2511-2516
4. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000) Cannabinoids control spasticityandtremor in amultiple sclerosismodel.Nature 404:84-87
5. Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z (1996) (-)-Delta9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271:9902-9905
6. Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V (2001) Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 15:2745-2747
7. Blázquez C, Casanova ML, Planas A, Gómez del Pulgar T, Villanueva C, Fernández-Aceñero MJ, Aragonés J, Huffman JW, Jorcano JL, Guzmán M (2003) Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17:529-531
8. Bouaboula M, Poinot-Chazel C, Bourrié B, Canat X, Calandra B, Rinaldi-Carmona M, Le Fur G, Casellas P (1995) Activation of mitogen-Activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312:637-641
9. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrié B, Rinaldi-Carmona M, Calandra B, Le Fur G, Casellas P (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of bothmitogen-Activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237:704-711
10. Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A, Bouaboula M, Galiègue S, Mondière P, Pénarier G, Le Fur G, Defrance T, Casellas P (1998) Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92:3605-3615
11. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, Jorcano JL, GuzmánM(2003) Inhibitionof skintumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111:43-50
12. Chan GC, Hinds TR, Impey S, Storm DR (1998) Hippocampal neurotoxicity of Δ9-Tetra Hydrocannabinol. J Neurosci 18:5322-5332
13. Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR (1996) Toxicity and carcinogenicity of Δ9-Tetra Hydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 30:109-117
14. Chen Y, Buck J (2000) Cannabinoids protect cells from oxidative cell death: A receptor independent mechanism. J Pharmacol Exp Ther 293:807-812
15. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 95:8375-8380
16. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, Girault JA (2003) Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23:2371-2382
17. Derocq JM, Segui M, Marchand J, Le Fur G, Casellas P (1995) Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 369:177-182
18. Derocq JM, Jbilo O, Bouaboula M, Ségui M, Clère C, Casellas P (2000) Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem 275:15621-15628
19. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691
20. Downer EJ, Fogarty MP, Campbell VA (2003) TetraHydroCannabinol-induced neurotoxicity depends on CB1 receptor mediated c-Jun N-Terminal kinase activation in cultured cortical neurons. Br J Pharmacol 140:547-557
21. Faubert Kaplan BL, Kaminski NE (2003) Cannabinoids inhibit the activation of ERK MAPK in PMA/Io-stimulated mouse splenocytes. Int Immunopharmacol 3:1503-1510
22. Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M (1989) Nonpsychotropic cannabinoid acts as a functional N-methyl-D-Aspartate receptor blocker. Proc Natl Acad Sci USA 86:9584-9587
23. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N(2003)Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 23:7767-7775
24. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-1066
25. Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, Biegon A, Mechoulam R, Shohami E (1997) Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 283:918-924
26. Galve-Roperh I, Sánchez C, Cortés M, Gómez del Pulgar T, Izquierdo M, Guzmán M (2000) Antitumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6:313-319
27. Galve-Roperh I, Rueda D, Gómez del Pulgar MT, Velasco G, Guzmán M (2002) Mechanism of extracellular signal-regulated kinase activation by the CB1 cannabinoid receptor.Mol Pharmacol 62:1385-1392
28. Giuffrida A, Parsons LH, Kerr TM, Rodríguez De Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363
29. Gómez del Pulgar T, Velasco G, GuzmánM(2000) The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347:369-373
30. Gómez del Pulgar T, De Ceballos ML, Guzmán M, Velasco G (2002a) Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277:36527-36533
31. Gómez del Pulgar T, Velasco G, Sánchez C, Haro A, Guzmán M(2002b) De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 363:183-188
32. Guzmán M (2003) Cannabinoids: Potential anticancer agents. Nat Rev Cancer 3:745-755
33. Guzmán M, Galve-Roperh I, Sánchez C (2001) Ceramide: A new second messenger of cannabinoid action. Trends Pharmacol Sci 22:19-22
34. Hampson AJ, Grimaldi M (2001) Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci 13:1529-1536
35. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and Δ9-Tetra Hydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268-8273
36. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikonomidou C, Schmid HH, Fernández-Ruiz JJ, Hansen HS (2001) Anandamide, but not 2-Arachydonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 78:1415-1427
37. Howlett AC (1984) Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35:1803-1810
38. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202
39. Jones S, Howl J (2003) Cannabinoid receptor systems: Therapeutic targets for tumour intervention. Expert Opin Ther Targets 7:749-758
40. Kaminski NE(1998)Regulation of thecAMPcascade, gene expression andimmune function by cannabinoid receptors. J Neuroimmunol 83:124-132
41. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H(2003) The cannabinoid system and immune modulation. J Leukoc Biol 74:486-496
42. Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A (2002) Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial. Crit Care Med 30:548-554
43. Lastres-Becker I, DeMiguel R, Fernández-Ruiz JJ (2003) The endocannabinoid system and Huntington's disease. Curr Drug Target CNS Neurol Disord 2:335-347
44. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyanis A, Kunos G(2000) Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346:835-840
45. Maccarrone M, Finazzi-Agro A (2003) The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ 10:946-955
46. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1. J Neurochem 80:448-456
47. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, López- Rodríguez ML, Casanova E, Schutz G, Zieglgansberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88
48. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor effects of cannabidiol, a non-psychotropic cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308:838-845
49. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
50. McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti M (2002a) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100:627-634
51. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS (2002b) Δ9-Tetra Hydro-Cannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 302:451-465
52. Mechoulam R, Spatz M, Shohami E (2002) Endocannabinoids and neuroprotection. Sci STKE 129:RE5
53. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzmán M, DiMarzo V (1999) Involvement of the cAMP/protein kinase pathway and of mitogen-Activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 463:235-240
54. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V (2000) Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141:118-126
55. Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP (2003) Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56:1-12
56. Molina-Holgado E, Vela JM, Arévalo-Martín A, Almazán G, Molina-Holgado F, Borrell J, Guaza C (2002) Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol 3-kinase/Akt signaling. J Neurosci 22:9742-9753
57. Muller-Vahl KR(2003) Cannabinoids reduce symptoms ofTourette's syndrome. ExpertOpin Pharmacother 4:1717-1725
58. Munro S, Thomas KL, Abu Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65
59. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA (1975) Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55:597-602
60. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, GreenbergDA (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19:2987-2995
61. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2AG) is neuroprotective after brain injury. Nature 413:527-531
62. Parmentier-Batteur S, Jim K, Mao O, Xie L, Greenberg DA(2002) Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 22:9771-9775
63. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884
64. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M (2003) Inhibitory effects of cannabinoidCB1receptor stimulationontumor growth and metastatic spreading: Actions on signals involved in angiogenesis and metastasis. FASEB J 17:1771-1773
65. Riboni L, Campanella R, Bassi R, Villani R, Gaini SM, Martinelli-Boneschi F, Viani P, Tettamanti G(2002)Ceramide levels are inversely associatedwith malignantprogression of human glial tumors. Glia 39:105-113
66. Roth MD, Baldwin GC, Tashkin DP(2002) Effects of delta-9- Tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 31:229-239
67. Rueda D, Galve-Roperh I, Haro A, Guzmán M (2000) The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-Terminal kinase. Mol Pharmacol 58:814-820
68. Rueda D, Navarro B, Martínez-Serrano A, Guzmán M, Galve-Roperh I (2002) The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J Biol Chem 277:46645-46650
69. Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H (2003) Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170:4953-4962
70. Sánchez C, Galve-Roperh I, Canova C, Brachet P, Guzmán M (1998a) Δ9-Tetra Hydro-Cannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436:6-10
71. Sánchez C, Galve-Roperh I, Rueda D, Guzmán M (1998b) Involvement of sphingomyelin hydrolysis and the mitogen-Activated protein kinase cascade in the Δ9-Tetra Hydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 54:834-843
72. Sánchez C, De Ceballos ML, Gómez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramón y Cajal S, Guzmán M(2001a) Inhibition of gliomagrowth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res 61:5784-5789
73. Sánchez C, Rueda D, Ségui B, Galve-Roperh I, Levade T, Guzmán M (2001b) The CB1cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. Mol Pharmacol 59:955-959
74. Sarker KP, Biswas KK, Yamakuchi M, Lee KY, Hahiguchi T, Kracht M, Kitajima I, Maruyama I (2003) ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. J Neurochem 85:50-61
75. Scallet AC, Uemure E, Andrews A, Ali SF, McMillan DE, Paule MC, Brown RM, Slikker W (1987) Morphometric studies of the rat hippocampus following chronic delta-9-Tetrahydrocannabinol (THC). Brain Res 436:193-198
76. Schwarz H, Blanco FJ, Lotz M(1994) Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 55:107-115
77. Shen M, Thayer SA (1998) Cannabinoid receptor agonist protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 54:459-462
78. Sinor AD, Irvin SM, Greenberg DA (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 278:157-160
79. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, Leon A (1996) The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 93:3984-3989
80. Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-Term potentiation. Nature 388:773-778
81. Valk PJM, Hol S, Vankan Y, Ihle JN, Askew D, Jenkins NA, Gilbert DJ, Copeland NG, deBoth NJ, Löwenberg B, Delwel R (1997a) The genes encoding the peripheral cannabinoid receptor and α-L-fucosidase are located near a newly identified common virus integration site, Evi11. J Virol 71:6796-6804
82. Valk P, Verbarkel S, Vankan Y, Hol S, Mancham S, Ploemacher R, Mayen A, Löwenberg B, Delwel R (1997b) Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Blood 90:1448-1457
83. Valk PJ, Vankan Y, Joosten M, Jenkins NA, Copeland NG, Löwenberg B, Delwel R (1999) Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincides with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2. J Virol 73:3595-3602
84. Van der Stelt M, Veldhuis WB, Bär PR, Veldink GA, Vliegenthart JFG, Nikolay K (2001) Neuroprotection by Δ9-Tetra Hydrocannabinol, the main active compound of marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 21:6475-6479
85. Van der Stelt M, Veldhuis WB, Maccarrone M, Bar PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JF (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26:317-346
86. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, UK MS Research Group (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 362:1517-1526
87. Zhu W, Friedman H, Klein TW (1998) Δ9-Tetra HydroCannabinol induces apoptosis in macrophages and lymphocytes: Involvement of Bcl-2 and caspase-1. J Pharmacol Exp Ther 286:1103-1109